X4 Pharmaceuticals (XFOR) Receivables - Other (2017 - 2025)

X4 Pharmaceuticals (XFOR) has reported Receivables - Other for 9 consecutive years, with $715000.0 the latest figure, recorded in Q3 2025.

• For the quarter ending Q3 2025, Receivables - Other fell 33.36% year-over-year to $715000.0; the trailing twelve-month figure through Sep 2025 stood at $715000.0 (down 33.36% YoY), and the FY2024 full-year result was $640000.0, up 13.88% from the prior year.
• Receivables - Other slipped to $715000.0 in Q3 2025 per XFOR's latest filing, from $720000.0 in the prior quarter.
• Across five years, Receivables - Other topped out at $1.2 million in Q4 2022 and bottomed at $393000.0 in Q3 2023.
• Historically, Receivables - Other has averaged $778315.8 across 5 years, with a median of $747000.0 in 2021.
• The sharpest annual moves came in 2023 and 2024: Receivables - Other sank 56.77% in 2023, then soared 173.03% in 2024.
• Over 5 years, Receivables - Other stood at $747000.0 in 2021, then jumped by 54.22% to $1.2 million in 2022, then slumped by 51.22% to $562000.0 in 2023, then increased by 13.88% to $640000.0 in 2024, then advanced by 11.72% to $715000.0 in 2025.
• According to Business Quant data, Receivables - Other over the past three periods registered $715000.0, $720000.0, and $665000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.